Out-of-Specification Investigations Under Health Canada GMP: What Your Lab Procedure Must Include

An out-of-specification (OOS) result that takes 60 days to close — with incomplete root cause documentation — is one of the fastest ways to draw scrutiny during a Health Canada GMP inspection. We’ve seen it happen repeatedly: the lab investigation itself is reasonably thorough, but the written procedure backing it up has gaps that an inspector finds within the first 20 minutes of a document review.

OOS investigation findings are a consistent feature of Health Canada inspection reports. The underlying issue is rarely that manufacturers don’t investigate. It’s that the written SOP doesn’t define the investigation process precisely enough to make the results defensible. Here’s exactly what Canada’s GMP framework expects — and where most pharmaceutical manufacturers leave themselves exposed.

What Canada GMP Guidelines Require for OOS Events

Health Canada’s GMP requirements for drug manufacturers are anchored in Part C, Division 2 of the Food and Drug Regulations (C.02.006 through C.02.029) and elaborated in the associated guidance document GUI-0001 (Good Manufacturing Practices Guidelines). GUI-0001 doesn’t use the term “OOS” as a formal defined term, but it’s unambiguous on the underlying quality system obligations: all analytical results must be documented, all anomalies must be investigated, and no batch may be released until deviations are fully resolved.

The most directly applicable framework comes from Health Canada’s adoption of ICH Q10 (Pharmaceutical Quality System). ICH Q10 treats OOS results as quality events requiring a structured, documented investigation — and Canada’s implementation of ICH Q10 means the two-phase investigation approach you’ll recognize from FDA guidance is equally expected north of the border.

What Health Canada inspectors look for is a written, SOP-level procedure that defines the investigation process before an OOS event ever occurs. If your OOS SOP was drafted during the last inspection prep cycle and hasn’t been tested against an actual OOS event since, that’s a risk worth addressing now.

The Two-Phase Investigation Process: What Each Phase Must Actually Accomplish

The two-phase framework isn’t just convention — it’s the structure that separates a defensible OOS file from one that creates regulatory exposure.

Phase 1: Laboratory Investigation

Phase 1 is confined entirely to the laboratory. The objective is to determine whether an assignable laboratory error accounts for the OOS result before any conclusion is drawn about the manufacturing process.

Acceptable Phase 1 activities include:

• Examining raw data, instrument printouts, and logbooks for transcription or calculation errors
• Confirming that instruments were calibrated and qualified at the time of testing
• Checking sample preparation records for volumetric or weighing errors (even a 0.5% weighing deviation can shift a result out of specification for a tight acceptance criterion)
• Having a second analyst independently review the data and preparation records

What’s not acceptable in Phase 1: initiating a re-test simply because the result is unexpected. Health Canada GMP expectations are clear that re-testing is appropriate only when a specific, identifiable error is suspected — not as a fishing expedition. Using passing re-test results to average away a failing original result is explicitly problematic and will be cited if the investigation file shows it occurred.

If Phase 1 identifies no assignable laboratory error, that conclusion must be documented and Phase 2 must begin automatically. The escalation can’t be left to individual judgment calls — your SOP has to make the handoff mandatory.

Phase 2: Full Process Investigation

Phase 2 expands the investigation to the manufacturing environment. It typically involves:

• A detailed review of the batch production record for deviations, substitutions, or operator notes
• Examination of raw material COAs and in-process testing data for the affected batch
• Review of equipment cleaning and maintenance logs
• Assessment of whether other batches manufactured under the same conditions may be affected
• Interviews with production personnel, documented in writing

Phase 2 investigations need a defined target completion timeline. Many Canadian pharmaceutical manufacturers set a 30-calendar-day target for full OOS closure; Health Canada doesn’t prescribe a specific number, but leaving an investigation open without documented justification for the delay is consistently flagged. A prolonged open OOS with a batch in quarantine is a business problem as much as a regulatory one.

At the end of Phase 2, the investigation must reach a documented conclusion: assignable cause identified (with correction and CAPA triggered), no assignable cause found (requiring a scientifically justified batch disposition decision), or authorized additional testing defined by the SOP. Batch disposition — release, reject, or retest — must follow directly from that conclusion and must be signed off by a qualified person with the documented authority to do so.

The 8 Elements Health Canada GMP Inspectors Check in Your OOS Procedure

During a Health Canada GMP inspection, inspectors typically pull two or three recent OOS investigation files and map them against your written SOP line by line. The procedure needs to contain all of the following.

1. Scope and applicability. Does the procedure apply to finished product testing only, or does it also cover in-process results, raw material testing, stability samples, and environmental monitoring data? Ambiguous scope is a frequent citation — especially when a stability OOS was handled differently from a finished product OOS without documented justification for the distinction.

2. Definitions. OOS, out-of-trend (OOT), and atypical result are not the same thing, and they don’t require the same investigation response. Your procedure must define each term and specify what triggers a formal investigation versus what triggers a notification or trend review.

3. Phase 1 investigation steps with explicit decision criteria. Every step — who performs it, what records they examine, and what specifically constitutes “no assignable laboratory cause” — needs to be written into the procedure. If the investigation file documents steps not described in the SOP, that’s a procedural deviation. If the SOP describes steps that weren’t performed, that’s also a finding.

4. Re-test and re-sample authorization. The conditions under which a second-analyst re-test or a re-sample from the original batch is permitted must be defined in advance. The maximum number of re-tests allowed and how results are interpreted in aggregate must be specified. This is one of the highest-risk areas for inspection findings and one of the easiest to tighten with precise SOP language.

5. Escalation and notification triggers. At what point does a QA manager need to be notified? If the OOS involves a batch that has already been distributed, who initiates a field alert assessment? These escalation paths must be written into the procedure — not left to individual judgment on a case-by-case basis.

6. Documentation requirements for each phase. Specify which forms are used, whether the investigation is recorded in a paper system or an electronic QMS, what attachments are required (instrument printouts, raw data copies, analyst signatures), and who reviews and approves each phase before it’s considered closed.

7. CAPA integration. An OOS investigation that reaches Phase 2 — even one that doesn’t identify a root cause — requires a CAPA assessment. Your procedure needs to state when CAPA is triggered automatically versus when a QA evaluation determines whether one is needed. Inspectors look for this integration point specifically, and a gap here signals a quality system that isn’t connected.

8. Batch disposition authority. The procedure must state, without ambiguity, who holds the authority to make the final batch disposition decision. Shared or unclear authority between QC and production is a systemic gap that gets flagged consistently.

Where Canadian Manufacturers Most Often Fall Short

Based on our experience supporting Canadian pharmaceutical manufacturers, CROs, and CMOs through Health Canada GMP inspection readiness reviews, these are the OOS documentation gaps that appear most consistently.

Re-testing without documented justification. This is the single most common OOS-related citation we encounter. A re-test was performed — sometimes multiple re-tests — without any record of what specific error was suspected. The SOP didn’t prohibit it; it just didn’t require the justification. The fix is simple: add a required field to your Phase 1 investigation form where the analyst must document the suspected error type before initiating any re-test.

Phase 1 conducted entirely by the original analyst. Health Canada GMP expectations align with the principle that re-testing in Phase 1 involves at least a second analyst or a documented supervisor review of the original data. Procedures that allow the original analyst to self-investigate and then authorize their own re-test are questioned during inspections.

No timeline tracking between investigation phases. The investigation was completed and closed, but there’s no documented date for when Phase 1 concluded and Phase 2 was initiated. Without those timestamps, an inspector can’t assess whether the phase transition was timely or whether the investigation sat dormant for two weeks.

Stability OOS handled under a separate, inconsistent procedure. Some sites maintain a standalone stability program SOP that doesn’t align with the main OOS procedure on re-test authorization or batch disposition triggers. Inconsistencies between procedures covering the same type of event — without documented scientific rationale for the difference — are flagged.

Contract lab OOS not addressed. If you outsource testing to a Canadian contract laboratory — or to an international CRO — your OOS procedure needs to explain what happens when the contract lab reports an OOS result. Who conducts Phase 1: the contract lab under their own procedure, or your QA team? Who holds final batch disposition authority? Your quality agreement and your OOS SOP need to give consistent, complementary answers to these questions. When they don’t, inspectors notice.

A Practical Starting Point

If your OOS procedure hasn’t been reviewed against a current Health Canada GMP inspection checklist in the past 18 months, start there. Map each of the 8 elements above against your current SOP and document the gaps. For each gap, assess whether it’s a language revision (a straightforward SOP update that takes days) or a systemic quality program issue (which requires a CAPA and possibly a lookback review of recent OOS files before your next inspection).

The gaps that create the most regulatory risk aren’t the complicated ones. Re-test authorization language and escalation triggers are both relatively easy to tighten in a single SOP revision. But if those language gaps have contributed to actual mishandlings — re-tests run without justification, Phase 2 escalations that didn’t happen on time — then the SOP update needs to be paired with analyst retraining and a documented review of recent OOS files.

Our team works with pharmaceutical manufacturers, CROs, and CMOs across Canada to assess OOS programs as part of broader Health Canada GMP readiness reviews. If your last inspection surfaced laboratory investigation findings — or if you’re preparing for your first inspection under Canada GMP requirements — a targeted SOP gap assessment is typically the fastest path to a defensible position before the inspector arrives.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025-Accredited Pharmaceutical Testing for US and Canadian Drug Manufacturers — Qalitex Laboratories provides cGMP-aligned analytical testing with full traceability documentation for cross-border pharma submissions.
• EU GMP Gap Assessments and Regulatory Consulting for Canadian Exporters — Care Europe helps Canadian pharmaceutical and NHP manufacturers assess European GMP readiness and navigate EU market entry requirements.